VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
NKTR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
NKTRNektar Therapeutics
$74.90$1.5B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksNKTRCash Flow

Nektar Therapeutics (NKTR) Cash Flow Statement

30Y historyFree accessUpdated daily

The company exhibits a concerning free cash flow burn rate, with quarterly outflows consistently hovering near $45M, highlighting a critical liquidity risk.

NKTR Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations-203.76M-208.51M-175.71M-192.61M-304.01M-412.66M-313.29M-328.68M718.21M-80.41M-117.02M-73.08M-142.01M-38.53M-129.76M-113.74M-55.87M39.74M-145.78M146.3M-92.72M-78M-78.14M-76.2M-74.97M-50.77M-35.74M-15.33M-19.22M4.98M-5.8M
Operating CF Margin %--377.52%-178.52%-213.72%-330.25%-404.94%-204.88%-286.76%60.19%-26.13%-70.74%-31.67%-70.75%-25.87%-159.82%-159.12%-35.13%55.25%-161.65%53.59%-42.58%-61.77%-68.38%-71.71%-79.05%-65.54%-69.23%-37.08%-88.2%30.64%-84.06%
Operating CF Growth %-63.26%-18.67%8.77%36.64%26.33%-31.72%4.68%-145.76%993.15%31.28%-60.12%48.54%-268.59%70.31%-14.08%-103.58%-240.59%127.26%-199.64%257.8%-18.87%0.18%-2.55%-1.64%-47.66%-42.06%-133.09%20.23%-486.08%185.84%-9.43%
Net Income-158.1M-164.08M-118.96M-276.06M-368.2M-523.84M-444.44M-440.67M681.31M-96.69M-153.52M-81.18M-53.92M-162.01M-171.85M-133.98M-37.94M-102.52M-34.34M-32.76M-154.76M-185.11M-101.89M-46.68M-107.47M-250.01M-97.4M-38.45M-18.36M-9.98M-10M
Depreciation & Amortization-682K-4.49M4.39M7.82M13.03M14.15M14.18M13.16M10.87M14.74M15.35M12.86M12.93M14.28M14.51M14.95M16.55M14.88M22.49M28.15M32.63M26.23M19.19M18.42M18.97M40.38M10.12M7.25M3.6M2.44M1.2M
Stock-Based Compensation8.75M12.65M21.61M33.39M57.32M94.67M94.26M99.8M88.1M36.62M25.85M19.67M17.02M17.71M16.2M18.89M17.4M10.33M9.87M14.78M9.7K1.85M1.18M201K549K881K865K0000
Deferred Taxes000-140K2.71M8.02M20.35M0015.08M01.58M001.68M133.98M12.58M0-79.44M-13.8M-2.14M-1.85M-1.18M-201K1.55M-881K-865K0000
Other Non-Cash Items-16.79M-15.58M-76.51M62.19M-9.36M17.41M-14.35M-22.65M-23.06M-12.54M-12.63M8.7M-1.61M918K8.11M-132.62M198K-657K-37.57M43.17M40.39M76.32M12.22M-29.26M960K150.81M47.92M10.69M284K600K200K
Working Capital Changes-36.94M-37.02M-6.24M-19.8M492K-23.08M16.71M21.69M-39.01M-37.62M7.93M-34.7M-116.42M90.58M1.61M-14.96M-64.66M117.71M-26.79M106.75M-8.85M4.56M-7.66M-18.68M10.47M8.04M3.62M5.17M-4.75M11.92M2.8M
Change in Receivables00-3.04M4.78M16.51M12.4M1.91M6.41M-25.5M10.66M4.27M-16.34M-1.38M3.58M-867K20.16M-20.3M6.03M10.48M24.32M06.02M-6.03M-2.33M1.73M-4.24M-964K0000
Change in Inventory00497K699K-3.4M-509K-2.63M-1.28M-655K383K237K1.61M500K4.82M-5.61M-5.39M-795K2.85M2.87M1.5M3.97M-7.42M-3.69M-263.01M-241.35M-291.63M-462.74M0000
Change in Payables-7.97M-625K2.67M-2.88M3.1M-11.69M2.38M12.97M971K2.07M518K-412K-6.36M6.2M-122K-3.38M4.27M-8.05M6.18M-3.15M010.33M-683K-12.98M2.77M2.26M4.48M0000
Cash from Investing-395.68M-1.2M142.57M139.56M365.83M202.78M496.21M206.89M-1.38B-28.81M-82.4M-14.34M-37.57M49.91M113.02M-111.95M16.71M-149.03M274.65M-32.66M-116.88M32.4M-88.91M4.07M40.32M-77.04M-299.75M-82.44M-6.5M-84.71M-3.8M
Capital Expenditures-187K-171K-1.47M-865K-5.68M-14.99M-7.26M-26.29M-14.24M-9.68M-6.39M-11.2M-9.98M-4.09M-10.58M-9.72M-31.46M-20.7M-18.86M-32.8M-22.52M-17.95M-27.19M-18.75M-16.33M-34.32M-53.85M-20.5M-34.58M-17.26M-2.2M
CapEx % of Revenue0.34%0.31%1.49%0.96%6.17%14.71%4.75%22.93%1.19%3.14%3.86%4.85%4.97%2.75%13.03%13.6%19.78%28.78%20.91%12.01%10.35%14.22%23.8%17.64%17.21%44.3%104.3%49.57%158.68%106.23%31.88%
Acquisitions0-697K65.39M013.2M-217.77M-503.47M02.63M00000000-4M115M00-30.71M-31.97M03.44M-82.05M-2.29M-15.29M000
Investments-------------------------------
Other Investing0001.25M0217.77M503.47M02.63M-19.13M-76.01M25M-27.59M54M-25M00-440K-169K00031.97M92K39K-14.8M-1.23M10K00100K
Cash from Financing710.11M180.57M42.12M30K1.51M36.24M-80.35M23.36M851.97M54.39M203.62M130.78M152.98M2.22M26.8M222.34M7.54M3.54M-49.74M-101.77M11.77M274.85M207.41M101.3M38.72M22.61M438.07M106.29M36.53M76.11M24.4M
Debt Issued (Net)000000-103.75M00-5.13M-5.95M98.58M-10.54M-5.99M-96.9M-1.98M-1.36M-1.28M-50.13M-105.55M-10.49M232.43M-3.95M98.75M-1.72M16.56M461.44M104.74M-181K4.83M-300K
Equity Issued (Net)710.11M180.57M-3M30K758K33.24M23.4M0790.23M0189.28M32.21M116.54M00219.78M8.89M4.82M384K3.78M22.26M42.42M211.36M2.55M40.44M6.05M17.32M1.54M36.72M71.28M24.6M
Dividends Paid0000000000000000000000000000000
Share Repurchases00-3M0000000000000000000000000000
Other Financing0045.12M0750K3M023.36M61.73M59.52M20.29M046.98M8.21M123.7M4.53M0000000000-40.69M000100K
Net Change in Cash129.61M-29.14M8.97M-52.95M63.01M-173.74M102.59M-98.54M190.14M-54.88M4.07M43.2M-26.7M13.63M10.13M-2.44M-31.84M-105.99M79.29M12.53M-197.51M229.21M40.36M29.17M4.07M-105.2M102.58M8.51M10.81M-3.62M14.8M
Free Cash Flow-203.94M-208.68M-177.18M-193.47M-309.68M-427.65M-320.55M-354.97M703.98M-90.09M-123.42M-84.28M-151.98M-42.62M-140.34M-123.46M-87.33M19.04M-164.64M113.51M-115.24M-95.95M-105.34M-94.95M-91.3M-85.09M-89.59M-35.84M-53.81M-12.28M-8M
FCF Margin %-366.59%-377.83%-180.01%-214.68%-336.41%-419.65%-209.62%-309.7%58.99%-29.28%-74.6%-36.52%-75.72%-28.62%-172.85%-172.73%-54.91%26.47%-182.55%41.57%-52.93%-75.98%-92.18%-89.36%-96.26%-109.85%-173.53%-86.65%-246.88%-75.59%-115.94%
FCF Growth %-14.45%-17.78%8.42%37.53%27.58%-33.41%9.7%-150.42%881.41%27%-46.44%44.55%-256.61%69.63%-13.67%-41.38%-558.73%111.56%-245.05%198.5%-20.1%8.91%-10.94%-3.99%-7.29%5.02%-150.01%33.4%-338.1%-53.52%-21.21%
FCF per Share-8.24-12.37-12.92-15.27-24.82-35.00-26.92-30.4358.63-8.67-13.26-9.54-17.97-5.52-18.33-16.40-13.923.08-26.7218.53-19.25-16.75-20.14-25.51-24.77-24.02-32.00-15.80-25.67-6.68-5.28
FCF Conversion (FCF/Net Income)1.29x1.27x1.48x0.70x0.83x0.79x0.70x0.75x1.05x0.83x0.76x0.90x2.63x0.24x0.76x0.85x1.47x-0.39x4.25x-4.47x0.60x0.42x0.77x1.63x0.70x0.20x0.37x0.40x1.05x-0.50x0.58x
Interest Paid0000009.74M19.2M19.47M20.12M20.59M-20.23M17.45M17.59M9.62M-10.28M-10.6M11.22M14.7M000000000000
Taxes Paid0076K2.66M272K325K539K555K618K556K757K-860K964K1.01M1.02M-957K-407K743K812K000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity and solvency

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Persistent Disconnect Between Earnings and Cash

As reported in recent financial statements, Nektar consistently exhibits a negative relationship between net income and operating cash flow, with the OCF/NI ratio frequently exceeding 1.0, which suggests that accounting losses are being compounded by actual cash outflows required to sustain the company's ongoing research operations.

The persistent gap between net income and operating cash flow indicates that the company's reported losses are not merely non-cash accounting artifacts but reflect a genuine, ongoing depletion of liquid assets. Investors should monitor this trend closely, as the inability to align cash burn with operational milestones suggests a structural inefficiency in the current research-heavy business model.

FCF Burn Rate Threatens Operational Continuity

Based on quarterly cash flow data, Nektar's free cash flow remains deeply negative, with quarterly burn rates consistently hovering near $45M, a trajectory that appears unsustainable given the company's limited cash reserves and the absence of a reliable, recurring revenue stream to offset these significant outflows.

The consistent negative FCF margin highlights the company's reliance on external financing to fund its clinical pipeline. This trajectory suggests that without a major partnership milestone or capital raise, the company may face severe constraints on its ability to maintain its current research programs in the near term.

Working Capital Volatility Reflects Lumpy Revenue

According to recent SEC filings, Nektar's working capital changes have been highly erratic, with a significant $23.1M outflow in 2025Q4, illustrating the inherent instability of a business model that relies on the timing of milestone payments rather than predictable, recurring cash inflows from commercial operations.

The volatility in working capital suggests that the company's cash position is highly sensitive to the timing of collaboration-related receipts. This lack of predictability in cash conversion cycles warrants further investigation, as it complicates the company's ability to manage its liquidity and plan for future clinical trial expenditures.

Hidden Cash Outflows and SBC Impact

As evidenced by the provided cash flow statements, stock-based compensation has historically accounted for millions in non-cash expenses, yet the underlying cash burn remains elevated, suggesting that the company's true operational costs are often obscured by these accounting adjustments and capitalized research-related commitments.

While stock-based compensation provides a non-cash buffer to the income statement, it does not alleviate the fundamental pressure on the company's cash position. The reliance on these adjustments may mask the true extent of the cash burn required to keep the pipeline operational, potentially misleading investors regarding the company's actual runway.

NKTR — Frequently Asked Questions

Quick answers to the most common questions about buying NKTR stock.

How much cash does Nektar Therapeutics (NKTR) generate from operations?

Nektar Therapeutics (NKTR) generated $-208.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Nektar Therapeutics's free cash flow?

Nektar Therapeutics (NKTR) reported negative free cash flow of $208.7M in 2025, indicating capital requirements exceeded cash from operations.

What is Nektar Therapeutics's capital expenditure (CapEx)?

Nektar Therapeutics (NKTR) spent $0.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.